Shuping Han

Shuping Han


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
XWXing-Yun Wang
Xing-Yun Wang
XYXiangyun Yan
Xiangyun Yan
LZLe Zhang
Le Zhang
JCJinyang Cai
Jinyang Cai
YZYahui Zhou
Yahui Zhou
SHShuping Han
Shuping Han

14 March 2021 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
WCWenjuan Chen
Wenjuan Chen
XCXiaohui Chen
Xiaohui Chen
YQYun Qian
Yun Qian
XWXingyun Wang
Xingyun Wang
YZYahui Zhou
Yahui Zhou
SHShuping Han
Shuping Han

9 August 2012 in International Journal of Molecular Medicine
Verified
Journal Article
Closed access
LCLi Cao
Li Cao
LKLi-Ping Kong
Li-Ping Kong
ZYZhangbing Yu
Zhangbing Yu
SHShuping Han
Shuping Han
YBYun-Fei Bai
Yun-Fei Bai
XGXi-Rong Guo
Xi-Rong Guo
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

16 November 2020 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
YXYan Xu
Yan Xu
ZYZhangbin Yu
Zhangbin Yu
QLQianqian Li
Qianqian Li
JZJinjun Zhou
Jinjun Zhou
XYXiaoguang Yin
Xiaoguang Yin
SHShuping Han
Shuping Han
Background and aim: Human milk has potential protective effects against bronchopulmonary dysplasia (BPD). However, studies on the association between the dose of human milk and BPD in China are limited. This study aimed to evaluate the dose-dependent effects of human milk on BPD and other neonatal morbidities in very low birth weight (VLBW) infants. Methods: This retrospective cohort study of preterm infants was conducted on preterm infants of gestational age ≤ 34 weeks and birth weight < 1500 g admitted to the multicenter clinical research database for breastfeeding quality improvement in Jiangsu province. The multivariate analysis was performed to compare the effect outcomes of daily graded doses [1–24 mL/(kg · day), 25–49 mL/(kg · day), and ≥ 50 mL/(kg · day) of body weight] of human milk on neonatal outcomes throughout the first 4 weeks of life versus a reference group receiving no human milk. The models were adjusted for potential confounding variables. Results: Of 964 included infants, 279 (28.9%) received exclusive preterm formula, 128 (13.3%) received 1–24 ml/(kg · day), 139 (14.4%) received 25–49 ml/(kg · day), and 418 (43.4%) received ≥50 ml/(kg · day) human milk for the first 4 weeks of life. Compared with infants receiving exclusive formula, those receiving the highest volume of human milk daily [≥50 mL/(kg · day)] had lower incidences of BPD [27.5% in ≥50 mL/(kg · day) vs 40.1% in 0 mL/(kg · day) human milk, P = 0.001)], moderate and severe BPD [8.9% in ≥50 mL/(kg · day) vs 16.1% in 0 mL/(kg · day), P = 0.004], necrotizing enterocolitis [NEC; 3.8% in ≥50 mL/(kg · day) vs 10.8% in 0 mL/(kg · day), P = 0.001], late-onset sepsis [LOS; 9.3% in ≥50 mL/(kg · day) vs 19.7% in 0 mL/(kg · day), P <0.01], and extrauterine growth retardation [EUGR; 38.5% in ≥50 mL/(kg · day) vs 57.6% in 0 mL/(kg · day), P <0.01)]. The logistic regression indicated that those receiving ≥50 ml/kg · day human milk had lower odds of BPD [adjusted odds ratio (AOR) 0.453; 95% confidence interval (CI): 0.309, 0.666], moderate and severe BPD (AOR 0.430; 95% CI: 0.249, 0.742), NEC (AOR 0.314; 95% CI: 0.162, 0. 607), LOS (AOR 0.420; 95% CI: 0.263, 0.673), and EUGR (AOR 0.685; 95% CI: 0.479, 0.979). Conclusions: A daily threshold amount of ≥50 ml/(kg · day) human milk in the first 4 weeks of life was associated with lower incidence of BPD as well as NEC, LOS, and EUGR in VLBW infants. Trial registration: ClinicalTrials.gov Identifier: NCT03453502. Registration date: March 5, 2018. This study was retrospectively registered.

27 February 2013 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
DQDa-Ni Qin
Da-Ni Qin
LQLingmei Qian
Lingmei Qian
DHDe-Liang Hu
De-Liang Hu
ZYZhangbing Yu
Zhangbing Yu
SHShuping Han
Shuping Han
XHXiaoshan Hu
Xiaoshan Hu

29 July 2016 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
XLXuehua Liu
Xuehua Liu
MLMengmeng Li
Mengmeng Li
YPYuzhu Peng
Yuzhu Peng
XHXiaoshan Hu
Xiaoshan Hu
JXJing Xu
Jing Xu
SHShuping Han
Shuping Han
MicroRNAs (miRNAs) are small, non-coding single-stranded RNAs that suppress protein expression by binding to the 3′ untranslated regions of their target genes. Many studies have shown that miRNAs have important roles in congenital heart diseases (CHDs) by regulating gene expression and signaling pathways. We previously found that miR-30c was highly expressed in the heart tissues of aborted embryos with ventricular septal defects. Therefore, this study aimed to explore the effects of miR-30c in CHDs. miR-30c was overexpressed or knocked down in P19 cells, a myocardial cell model that is widely used to study cardiogenesis. We found that miR-30c overexpression not only increased cell proliferation by promoting cell entry into S phase but also suppressed cell apoptosis. In addition, we found that miR-30c inhibited dimethyl sulfoxide-induced differentiation of P19 cells. miR-30c knockdown, in contrast, inhibited cell proliferation and increased apoptosis and differentiation. The Sonic hedgehog (Shh) signaling pathway is essential for normal embryonic development. Western blotting and luciferase assays revealed that Gli2, a transcriptional factor that has essential roles in the Shh signaling pathway, was a potential target gene of miR-30c. Ptch1, another important player in the Shh signaling pathway and a transcriptional target of Gli2, was downregulated by miR-30c overexpression and upregulated by miR-30c knockdown. Collectively, our study revealed that miR-30c suppressed P19 cell differentiation by inhibiting the Shh signaling pathway and altered the balance between cell proliferation and apoptosis, which may result in embryonic cardiac malfunctions.